Accepted for Publication: December 20, 2011.
Author Contributions: Study concept and design: Diamond. Analysis and interpretation of data: Diamond, Pencharz, Feldman, Ling, Moore, and Wales. Drafting of the manuscript: Diamond. Critical revision of the manuscript for important intellectual content: Diamond, Pencharz, Feldman, Ling, Moore, and Wales. Study supervision: Pencharz, Feldman, Ling, Moore, and Wales.
Financial Disclosure: The authors have received investigator-initiated trial funding from Fresenius Kabi, the manufacturer of both Omegaven and Intralipid, to evaluate SMOFlipid for the prevention of IFALD. Dr Diamond is the recipient of a Graduate Studentship Award from the Canadian Liver Foundation and the Chisholm Memorial Fellowship, Post Graduate Medical Education Office, University of Toronto. Dr Diamond was also supported by a fellowship award from the Canadian Institutes of Health Research, with additional support from the Surgeon Scientist Training Program, Department of Surgery, University of Toronto. Dr Feldman is supported by a Canada Research Chair in Childhood Arthritis.
Additional Contributions: The following members of the Group for Improvement of Intestinal Function and Treatment team, our multidisciplinary intestinal rehabilitation program, provided contributions to our experience with and understanding of IFALD: J. Darch, J. Brennan-Donnan, J. Bowers, M. Carricato, K. Cormier, G. Courtney-Martin, L. Coxson, N. D’Amato, M. De Angelis, N. de Silva, A. Fecteau, D. Fierheller, D. Grant, A. Gold, D. Harrison, J. Hawes, L. Ives-Baine, P. Kean, C. Kosar, C. Koziolek, K. Lang, J. Maxwell, K. Murch, C. Newman, V. Ng, C. Patterson, A. Rogers, M. Rugg, and S. So.